ArticleScientific reports2016
Alteration of the serum microbiome composition in cirrhotic patients with ascites.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Predictive value of serum bile acids as metabolite biomarkers for liver cirrhosis: a systematic review and meta-analysis.Metabolomics : Official journal of the Metabolomic Society · 2022Pooled it
- The Role of Microbiota in Type 1 Diabetes: Insights into Dysbiosis and Immune Interactions.Nutrients · 2026Review
- Beyond conventional treatments: cutting-edge strategies for ascites in cirrhosis.Frontiers in medicine · 2026Review
- Pathological Alterations in Human Blood Microbiome-An Updated Review.International journal of molecular sciences · 2025Review
- Experimental tests challenge the evidence of a healthy human blood microbiome.The FEBS journal · 2025Article
- Blood microbiome signatures in systemic diseases: current insights, methodological pitfalls, and future horizons.Frontiers in cellular and infection microbiology · 2025Review
- Human reference microbiome profiles of different body habitats in healthy individuals.Frontiers in cellular and infection microbiology · 2025Article
- Lack of genotoxicity and subchronic toxicity in safety assessment studies ofToxicology reports · 2024Article
- Infections in decompensated cirrhosis: Pathophysiology, management, and research agenda.Hepatology communications · 2024Review
- Article
- Blood Microbiota and Its Products: Mechanisms of Interference with Host Cells and Clinical Outcomes.Hematology reports · 2024Review
- Article
- Changes of the bacterial composition in duodenal fluid from patients with liver cirrhosis and molecular bacterascites.Scientific reports · 2023Article
- Exploring the diversity of blood microbiome during liver diseases: Unveiling Novel diagnostic and therapeutic Avenues.Heliyon · 2023Review
- The Role of Gut Microbiome-Derived Short-Chain Fatty Acid Butyrate in Hepatobiliary Diseases.The American journal of pathology · 2023Review
- The Blood Microbiome and Health: Current Evidence, Controversies, and Challenges.International journal of molecular sciences · 2023Review
- Effects of dietary protein level on small intestinal morphology, occludin protein, and bacterial diversity in weaned piglets.Food science & nutrition · 2022Article
- Exploring blood microbial communities and their influence on human cardiovascular disease.Journal of clinical laboratory analysis · 2022Review
- Article
- Clinical Application and Progress of Fecal Microbiota Transplantation in Liver Diseases: A Review.Seminars in liver disease · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The progression of cirrhosis is associated with alterations in the composition of the gut microbiome. To assess microbial translocation, we compared the serum microbial composition of patients with and without ascites and characterized the ascitic fluid microbiome using 16S rDNA high-throughput sequencing data. A complex and specific microbial community was detected in the serum and ascitic fluid of patients with cirrhosis but barely detectable in the serum of healthy controls. The serum microbiome of patients with ascites presented higher levels of lipopolysaccharide binding protein, a marker of microbial translocation, associated with higher diversity and relative abundance of Clostridiales and an unknown genus belonging to the Cyanobacteria phylum compared to patients without ascites. The composition of the fecal microbiome was also more altered in patients with than without ascites, confirming previous studies on fecal microbiome. We propose that alteration of the serum and fecal microbiome composition be considered indicators of cirrhosis progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.